Want to see GB:CREO full AI Analyst Report?
CREO Stock Chart & Stats
13.00 p
0.13 p(0.92%)
At close: 4:00 PM EDT
13.00 p
0.13 p(0.92%)
Day’s Range― - ―
52-Week Range9.50 p - 18.50 p
Previous CloseN/A
Volume174.00K
Average Volume (3M)890.62K
Market Cap
£48.28M
Enterprise Value57.72M
Total Cash (Recent Filing)£12.40M
Total Debt (Recent Filing)£4.10M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Jun 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding449,139,980
10 Day Avg. Volume394,980
30 Day Avg. Volume890,617
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)0.82
Price to Sales (P/S)6.81
P/FCF Ratio-2.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)£9.10M
Bulls Say, Bears Say
Bulls Say
Manageable LeverageRelatively low leverage gives Creo greater financial flexibility while it scales its medical-device platform. A sizable equity base can support investment in commercialisation and product development, while limiting the immediate burden of debt service compared with a highly leveraged structure.
Improved 2025 RevenueThe return to revenue growth in 2025 indicates that customer demand or commercial execution improved after a stagnant prior year. If sustained, stronger sales can increase the installed base, drive consumables usage, and help spread fixed operating costs across a larger revenue base.
Recurring Consumables ModelCreo’s platform-and-consumables model can create recurring revenue after equipment is placed at hospitals and endoscopy providers. Growing procedure volumes should support repeat purchases, potentially improving revenue visibility and customer economics as the installed base expands over time.
Bears Say
Persistent Operating LossesLarge and persistent operating losses show that the current cost base remains well ahead of the company’s revenue scale. Until growth produces operating leverage, Creo may need continued investment to support commercial expansion without demonstrating that its core activities are self-sustaining.
Sustained Cash BurnRepeated negative operating and free cash flow means Creo is not yet funding its activities internally. Even though 2025 free cash flow improved versus 2024, sustained cash outflows can increase dependence on existing liquidity or future financing if profitability does not improve.
Unproven Core ProfitabilityA positive bottom-line result does not yet demonstrate durable earnings power because operating losses remained substantial. Reliance on non-operating items makes reported profit less representative of the underlying business and leaves profitability vulnerable unless core operations improve.
Creo Medical News
CREO FAQ
What was Creo Medical Group PLC’s price range in the past 12 months?
Creo Medical Group PLC lowest share price was 9.50 p and its highest was 18.50 p in the past 12 months.
What is Creo Medical Group PLC’s market cap?
Creo Medical Group PLC’s market cap is £48.28M.
When is Creo Medical Group PLC’s upcoming earnings report date?
Creo Medical Group PLC’s upcoming earnings report date is Jun 02, 2027 which is in 222 days.
How were Creo Medical Group PLC’s earnings last quarter?
Creo Medical Group PLC released its earnings results on Sep 30, 2026. The company reported -0.02 p earnings per share for the quarter.
Is Creo Medical Group PLC overvalued?
According to Wall Street analysts Creo Medical Group PLC’s price is currently Overvalued.
Does Creo Medical Group PLC pay dividends?
Creo Medical Group PLC does not currently pay dividends.
What is Creo Medical Group PLC’s EPS estimate?
Creo Medical Group PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Creo Medical Group PLC have?
Creo Medical Group PLC has 449,139,980 shares outstanding.
What happened to Creo Medical Group PLC’s price movement after its last earnings report?
Creo Medical Group PLC reported an EPS of -0.02 p in its last earnings report. Following the earnings report the stock price went down -12.421%.
Which hedge fund is a major shareholder of Creo Medical Group PLC?
Currently, no hedge funds are holding shares in GB:CREO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Creo Medical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.27%
12-Months-Change
Fundamentals
Return on Equity
-38.29%
Trailing 12-Months
Asset Growth
-17.44%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Creo Medical Group PLC
Creo Medical Limited, a UK-based enterprise and subsidiary of Creo Medical Group plc, specializes in the innovation and creation of electrosurgical medical devices for surgical endoscopy applications. Founded in 2003 as MicroOncology Ltd and headquartered in Chepstow, the company's core offering is Croma, an advanced energy platform. This platform is engineered to power a diverse collection of multi-modal instruments, thereby enhancing therapeutic interventions for both medical professionals and patients. Its extensive product portfolio includes specialized tools such as Speedboat Inject, an adaptable energy instrument designed for flexible endoscopic procedures; Speedboat Slim, a flexible bipolar radiofrequency (RF) and microwave device for precise tissue cutting and coagulation; MicroBlate Fine, a microwave needle for ablation; MicroBlate Flex, a flexible microwave ablation device; SlypSeal Flex, a flexible haemostasis device engineered to control upper and lower gastrointestinal bleeds; and SpydrBlade Flex, a flexible scissor-like instrument that integrates bipolar RF and microwave technology to grasp, cut, and coagulate highly vascularized tissues.